MA35281B1 - Dosage et administration d'anticorps anti-erbb3 en combinaison avec le paclitaxel pour le traitement de cancers gynécologiques - Google Patents

Dosage et administration d'anticorps anti-erbb3 en combinaison avec le paclitaxel pour le traitement de cancers gynécologiques

Info

Publication number
MA35281B1
MA35281B1 MA36703A MA36703A MA35281B1 MA 35281 B1 MA35281 B1 MA 35281B1 MA 36703 A MA36703 A MA 36703A MA 36703 A MA36703 A MA 36703A MA 35281 B1 MA35281 B1 MA 35281B1
Authority
MA
Morocco
Prior art keywords
paclitaxel
assay
treatment
administration
combination
Prior art date
Application number
MA36703A
Other languages
English (en)
Inventor
William Kubasek
Victor Moyo
Joseph Pearlberg
Isabelle Tabah-Fisch
Gavin Macbeath
Original Assignee
Merrimack Pharmaceuticals Inc
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrimack Pharmaceuticals Inc, Sanofi Sa filed Critical Merrimack Pharmaceuticals Inc
Publication of MA35281B1 publication Critical patent/MA35281B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des méthodes et des compositions pour le traitement clinique de cancers gynécologiques avancés à l'aide d'anticorps anti-erbb3 combinés avec le paclitaxel.
MA36703A 2011-06-30 2014-01-22 Dosage et administration d'anticorps anti-erbb3 en combinaison avec le paclitaxel pour le traitement de cancers gynécologiques MA35281B1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161503342P 2011-06-30 2011-06-30
US201161529630P 2011-08-31 2011-08-31
FR1250860 2012-01-30
US201261596102P 2012-02-07 2012-02-07
PCT/US2012/042164 WO2013003037A2 (fr) 2011-06-30 2012-06-13 Dosage et administration d'anticorps anti-erbb3 en combinaison avec le paclitaxel pour le traitement de cancers gynécologiques

Publications (1)

Publication Number Publication Date
MA35281B1 true MA35281B1 (fr) 2014-07-03

Family

ID=47424747

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36703A MA35281B1 (fr) 2011-06-30 2014-01-22 Dosage et administration d'anticorps anti-erbb3 en combinaison avec le paclitaxel pour le traitement de cancers gynécologiques

Country Status (16)

Country Link
US (1) US20140248280A1 (fr)
EP (1) EP2726100A4 (fr)
JP (1) JP2014527035A (fr)
KR (1) KR20140063578A (fr)
CN (1) CN103945866A (fr)
AU (1) AU2012275850A1 (fr)
BR (1) BR112013033544A2 (fr)
CA (1) CA2839869A1 (fr)
CO (1) CO6862110A2 (fr)
EA (1) EA201490180A1 (fr)
MA (1) MA35281B1 (fr)
MX (1) MX2013015333A (fr)
PH (1) PH12013502663A1 (fr)
TW (1) TW201317002A (fr)
UY (1) UY34178A (fr)
WO (1) WO2013003037A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG178789A1 (en) 2007-02-16 2012-03-29 Merrimack Pharmaceuticals Inc Antibodies against erbb3 and uses thereof
KR101798679B1 (ko) 2010-03-11 2017-11-16 메리맥 파마슈티컬즈, 인크. ３중 음성 및 기저형 유방암 치료 시의 ｅｒｂｂ３ 저해제의 용도
US9725511B2 (en) 2012-11-08 2017-08-08 Hoffmann-La Roche Inc. Anti-HER3/HER4 antibodies binding to the beta-hairpin of HER3 and the beta-hairpin of HER4
EP3087394A2 (fr) 2013-12-27 2016-11-02 Merrimack Pharmaceuticals, Inc. Profils de biomarqueur pour prédire les résultats d'une thérapie cancéreuse utilisant des inhibiteurs d'erbb3 et/ou des chimiothérapies
JP6755235B2 (ja) * 2014-07-16 2020-09-16 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 低悪性度漿液性癌におけるｈｅｒ３阻害
AU2016248329A1 (en) * 2015-04-17 2017-11-09 Merrimack Pharmaceuticals, Inc. Combination treatments with seribantumab
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
AU2017235450A1 (en) 2016-03-15 2018-08-16 Merrimack Pharmaceuticals, Inc. Methods for treating ER+, HER2-, HRG+ breast cancer using combination therapies comprising an anti-ErbB3 antibody

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100178651A1 (en) * 2006-11-03 2010-07-15 Christos Hatzis Bifunctional Predictors of Cancer Treatment Sensitivity and Resistance
SG178789A1 (en) * 2007-02-16 2012-03-29 Merrimack Pharmaceuticals Inc Antibodies against erbb3 and uses thereof
KR101798679B1 (ko) * 2010-03-11 2017-11-16 메리맥 파마슈티컬즈, 인크. ３중 음성 및 기저형 유방암 치료 시의 ｅｒｂｂ３ 저해제의 용도

Also Published As

Publication number Publication date
EP2726100A2 (fr) 2014-05-07
TW201317002A (zh) 2013-05-01
WO2013003037A3 (fr) 2014-05-01
KR20140063578A (ko) 2014-05-27
JP2014527035A (ja) 2014-10-09
UY34178A (es) 2013-01-31
AU2012275850A1 (en) 2013-03-21
US20140248280A1 (en) 2014-09-04
WO2013003037A2 (fr) 2013-01-03
BR112013033544A2 (pt) 2017-12-19
CA2839869A1 (fr) 2013-01-03
EP2726100A4 (fr) 2015-04-29
PH12013502663A1 (en) 2018-03-21
MX2013015333A (es) 2014-07-09
CO6862110A2 (es) 2014-02-10
EA201490180A1 (ru) 2014-08-29
CN103945866A (zh) 2014-07-23

Similar Documents

Publication Publication Date Title
FR25C1001I2 (fr) Compositions d'anticorps pour le traitement de tumeurs
EP2868667A4 (fr) Agent thérapeutique à base d'anticorps anti-bmp9 en tant que principe actif, pour le traitement de l'anémie, notamment une anémie rénale et une anémie liée à un cancer
EP2860188A4 (fr) Polypeptides et anticorps pour le traitement d'une infection par le vbh et maladies associées
MA37840A3 (fr) Immunoconjugués comprenant des anticorps anti-cd79b
EP2888283A4 (fr) Anticorps et vaccins utilisables en vue du traitement de cancers ror1 et de l'inhibition de la métastase
MA41013A (fr) Compositions comprenant des souches bactériennes
MA34277B1 (fr) Pyrrolobenzodiazépines et conjugués de celles-ci
EP2558493A4 (fr) Anticorps pour le traitement d'une infection et d'une maladie associées à clostridium difficile
EP2643018A4 (fr) Anticorps anti-il-6 utilisés pour le traitement de la stomatite
MA37538A2 (fr) Anticorps et immunoconjugués anti-ly6e et procédés d'utilisation
EA201391719A1 (ru) Хиназолиновые производные для лечения вирусных инфекций и дальнейших заболеваний
EP2552203A4 (fr) Composés et compositions pharmaceutiques pour le traitement d'infections virales
CL2012003427A1 (es) Compuestos derivados de 5-amino-3,6-dihidro-1h-pirazina-2-ona; y uso en el tratamiento de enfermedades tales como alzheimer, senilidad, demencia, entre otras.
EP2766012A4 (fr) Compositions utiles pour le traitement d'une néphropathie et leurs procédés de préparation
MA37946A1 (fr) Traitement de la polyarthrite rhumatoïde
MA35712B1 (fr) Anticorps anti-htra1 et leurs procédés d'utilisation
BR112014031310A2 (pt) anticorpos anti-pcsk9, formulações, dosagem e métodos de uso
EP2154971A4 (fr) Combinaison pharmaceutique synergique pour le traitement du cancer
MA38986B1 (fr) Inhibiteurs marqués de l'antigène membranaire spécifique de la prostate (psma), leur utilisation comme agents d'imagerie et agents pharmaceutiques pour le traitement du cancer de la prostate
EP2793882A4 (fr) Administration de promédicaments activés par l'hypoxie en combinaison à des inhibiteurs de chk1 pour le traitement du cancer
EP2726100A4 (fr) Anticorps anti-erbb3 en combinaison avec le paclitaxel pour le traitement de cancers gynécologiques
MA44700A (fr) Combinaison d'un anticorps anti-il-10 et d'un oligonucléotide de type cpg-c pour le traitement du cancer
MA38253A1 (fr) Compositions comprenant de la vortioxétine et du donépézil
EP2579867A4 (fr) Régime à base de triheptanoïne pour le traitement de la maladie des corps de polyglucosane de l'adulte (apbd)
EP2685990A4 (fr) Combinaison d'un oligonucléotide anti-clusterine et de l'inhibiteur hsp90 pour le traitement du cancer de la prostate